Floatz logo

ANTIBODY-DRUG CONJUGATE ANTI-TIM-1-VCMMAE CDX-014

Papillary Renal Cell Carcinoma

Celldex Therapeuticsantibody_drug_conjugatePhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

23 Active assets in the Papillary Renal Cell Carcinoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
First Affiliated Hospital, Sun Yat-Sen University
Phase 3BB
Pembrolizumab
First Affiliated Hospital, Sun Yat-Sen University
Phase 3BB
VOLITINIB
AstraZeneca
Phase 3BB
Bms-907351
National Cancer Institute (NCI)
Phase 2BB

View all 37 →

Same molecule, other indications

ANTIBODY-DRUG CONJUGATE ANTI-TIM-1-VCMMAE CDX-014 is also rated in:

nonpapillary renal cell carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
kidney neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
Ovarian Clear Cell CarcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →